

# Q1 2022 *results*

sanofi



• We're off to a good start in 2022 thanks to a strong commitment to our strategy. We're proud of the progress made in Immunology, with a broad pipeline of 13 potential new treatments in development. •

*Paul Hudson*

Chief Executive Officer, Sanofi

## Company sales and business EPS\*

€9,674m

+8.6% (+12.6%)

Q1 2022  
company sales \*\*



€1.94

+16.1% (+20.5%)

Q1 2022  
business EPS \*\*

\* Earnings per share

\*\* Growth rates are expressed at constant exchange rates (CER).  
Growth rates in parentheses are expressed on a reported basis.

## Sales by global business unit




€3,566m

Specialty Care



€3,760m

General Medicines



€1,020m

Vaccines



€1,328m

Consumer Healthcare

## Sales by geography

US

€3,484m

Europe

€2,392m



Rest of  
the World

€3,798m

## Progress on social impact strategy



First sustainability-linked  
bond indexed to  
access to medicines

Tied to Sanofi's commitment  
to improve access to essential  
medicines in 40 of the world's  
poorest countries via its non-profit  
unit Sanofi Global Health



Innovation for  
vulnerable communities

Sanofi is working with  
leading oncology institutions  
to tackle the challenge  
of pediatric cancer trials

For further information on Q1 2022 results  
and definitions of financial indicators, please refer  
to the press release issued on April 28, 2022 at:  
[www.sanofi.com/en/investors](http://www.sanofi.com/en/investors)

sanofi



@Sanofi



@Sanofi



@Sanofi



@SanofiaventisTVen